Pradaxa is a blood thinner, taken orally for the prevention of strokes and blood clots in patients with non-valvular atrial fibrillation. It was designed to replace Warfarin (also known as Coumadin).
Unfortunately, Pradaxa has now been associated with potentially fatal internal bleeding, with more than 200 reports of fatalities due to internal bleeding in Pradaxa patients worldwide. In the recent study, two Cleveland Clinic researchers found that Pradaxa increases the risk of a heart attack and an acute coronary syndrome by as much as one-third.
If you or a family member have taken Pradaxa and suffered a serious bleed or heart attack, please contact Galfand Berger, LLP at 1-800-222-8792 to schedule a free, no-obligation consultation with one of the firm’s knowledgeable Philadelphia products liability attorneys.